Breast Cancer Awareness: Early Detection, Risk Factors, and What Ghanaian Women Need to Know

Breast cancer is the most common cancer among women in Ghana and is responsible for more cancer deaths in Ghanaian women than any other malignancy. Unlike in high-income countries where breast cancer mortality has been declining due to widespread screening and improved treatment, Ghana continues to face high mortality rates — primarily because the majority of cases are diagnosed at advanced stages when treatment outcomes are significantly worse. Understanding breast cancer risk, the biology of the disease, and the available screening and detection methods is essential knowledge for every Ghanaian woman.

Understanding Breast Cancer: The Basics

Breast cancer is not a single disease — it is a heterogeneous group of cancers arising from different breast cell types, with different biological behaviours, different responses to treatment, and different prognoses. The major categories include:

Hormone Receptor-Positive (ER+/PR+) Breast Cancer

The most common subtype. These cancers express oestrogen and/or progesterone receptors, meaning female sex hormones drive their growth. They tend to grow more slowly and are responsive to hormone-blocking therapies (tamoxifen, aromatase inhibitors). They represent a higher proportion of breast cancers in post-menopausal women.

HER2-Positive Breast Cancer

Overexpression of the HER2 protein drives more aggressive tumour growth. These cancers were historically associated with poor prognosis, but targeted therapies (trastuzumab/Herceptin) have dramatically improved outcomes for HER2-positive disease. Access to trastuzumab in Ghana remains limited and expensive.

Triple-Negative Breast Cancer (TNBC)

Negative for oestrogen receptors, progesterone receptors, and HER2. TNBC is more common in women of African descent and in younger women. It is more aggressive, has fewer targeted treatment options, and is associated with worse outcomes — one of the reasons Ghanaian women face disproportionate breast cancer mortality. Chemotherapy is the primary treatment. TNBC has a strong association with BRCA1 gene mutations.

Risk Factors for Breast Cancer

Non-Modifiable Risk Factors

• Female sex (though men can develop breast cancer, women comprise 99% of cases)

• Increasing age — risk rises sharply after 40

• Family history: First-degree relative (mother, sister, daughter) with breast cancer approximately doubles lifetime risk

• BRCA1 and BRCA2 genetic mutations: Carry lifetime breast cancer risks of 55–85% and 45–65% respectively

• Dense breast tissue: Increases cancer risk and reduces mammographic sensitivity

Modifiable Risk Factors

• Obesity, particularly post-menopausal: Adipose tissue produces oestrogen — a driver of ER+ breast cancer

• Alcohol consumption: Risk increases proportionally with alcohol intake, with no 'safe' threshold for breast cancer

• Physical inactivity

• Hormone replacement therapy: Long-term combined (oestrogen-progestogen) HRT modestly increases risk

• Not breastfeeding: Breastfeeding is protective; each year of breastfeeding reduces breast cancer risk by approximately 4%

Early Detection: The Critical Role of Breast Awareness

Breast Self-Examination (BSE)

Every woman should know what her breasts normally feel and look like, so that changes are noticed promptly. A monthly self-examination — ideally at the same point in the menstrual cycle when breasts are least tender — involves looking in a mirror for shape changes, skin dimpling, or nipple changes, and feeling all breast tissue and axillary lymph nodes for lumps or thickening.

Any of the following should prompt immediate medical review: a new lump or thickening, change in breast size or shape, skin dimpling or tethering, nipple inversion or discharge (especially bloody discharge), or redness and warmth of the breast skin.

Clinical Breast Examination

A clinical examination by a trained healthcare provider is more sensitive than self-examination alone and should be part of every woman's annual health check from age 25–30 onwards.

Mammography

X-ray imaging of the breast that can detect cancers before they are palpable — typically 2–3 years before a lump becomes physically detectable. Mammography screening is the tool most responsible for breast cancer mortality reduction in high-income countries. In Ghana, mammography services are available at major teaching hospitals and some private centres but are not yet universally accessible. Women aged 40–74 should discuss mammography access with their doctor.

Breast Ultrasound

Particularly useful in younger women with denser breast tissue (where mammography is less sensitive) and for characterising palpable lumps. Widely available at private radiology centres in Ghana.

Blood Tests and Breast Cancer

There is no reliable blood-based screening test for breast cancer in the general population. CA 15-3 and CA 27.29 are tumour markers used for monitoring known breast cancer disease response to treatment — not for initial screening, where they lack adequate sensitivity. Genetic testing for BRCA1 and BRCA2 mutations is relevant for women with strong family history and is increasingly accessible in Ghana through referral to genetic counselling services.

�� Know your breasts. Examine monthly. Visit a clinician if anything changes. Every month you delay investigating a new breast lump is a month that matters. Ghana loses too many women to late diagnosis — be part of the change.